“Patient subpopulations that would benefit from nivolumab plus ipilimumab over nivolumab for HNSCC are yet to be identified, and further research to identify biomarkers to optimize patient selection and improve patient outcomes is warranted,” the study authors wrote. The investigators noted the research should continue to identify patient subgroups that may benefit from treatment with the combination. In patients with platinum-eligible disease, the ORR was 20.3% (95% CI, 13.6%-28.5%) in the nivolumab plus ipilimumab arm vs 29.5% (95% CI, 18.5%-42.6%) in the nivolumab alone arm. In patients with platinum-refractory disease, the overall response rate (ORR) was 13.2% (95% CI, 8.4%-19.5%) in the combination arm vs 18.3% (95% CI, 10.6%-28.4%) for patients in the monotherapy arm (odds ratio, 0.68 95% CI, 0.33-1.43 P =.
0 Comments
Leave a Reply. |